We are committed to changing the lives of patients by applying our knowhow and innovative technologies to develop novel, value-add medicines based on real-world data and our knowledge of established products.
We have to date built a broad proprietary pipeline of 11 innovative, value-add drug candidates which we expect will all utilize the FDA’s 505(b)(2) regulatory pathway. The pipeline currently consists of a number of cardiovascular product candidates, of which the majority we intend to commercialise with our own sales force targeting a group of cardiovascular specialists and hospitals in the U.S. In addition, we are also pursuing other value-add candidates targeting other blockbuster markets.
We currently have two products on the market.